To reverse Antibiotic Resistance

The ActiSense™ technology creates a selection pressure to reverse antibiotic resistance and thus, sustains an antibiotic sensitive environment (including human tissues and microbiome). The concept is based on the “dual action” of a CRISPR-associated 3 (Cas3) encoding plasmid, guided by multiple sequences that on the one hand, target the antibiotic-resistance genes and destroy them, while on the other hand in parallel, protect bacteria harboring this plasmid against a second “attacking” phage-based particle releasing a growth-inhibitor-encoding plasmid that kills unprotected bacteria.

This is a key feature. This strategic linkage results in a population shift where all bacteria that now grow will once again be sensitive to antibiotics. The system consequently, harbors sequences that target many different resistance genes.